A Registered Cohort Study of Inflammatory Demyelination Disease

A Registered Cohort Study on Natural Course and Drug Efficacy of Inflammatory Demyelination Disease

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04386018

Enrollment

400

Registered

2020-05-13

Start date

2020-05-15

Completion date

2025-04-01

Last updated

2020-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Demyelinating Autoimmune Diseases, CNS

Brief summary

This study will provide further insights into the natural course of Inflammatory demyelination disease including clinical features，progression, related antibody spectrum and drug treatment effect

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Yes

Inclusion criteria

1. Outpatient or inpatient 2. Meet the diagnostic criteria of Inflammatory Demyelination Disease. 3. Voluntary participation and informed consent signed by the applicant or his/her family.

Exclusion criteria

1. Severe complications 2. Poor prognosis (\<1 year survival) 3. Severe mental disorder and inability to cooperate with the examination.

Design outcomes

Primary

Measure	Time frame	Description
The correlation between clinical phenotypes and Serum antibodies	from date of enrollment until the date of death from any cause,assessed up to 20 years	Different clinical subtypes of Demyelinating Autoimmune Diseases have different course and prognosis.It may be related to different serum antibodies.

Countries

China

Contacts

Primary ContactJin Bi, BA

2311306109@qq.com86-13673527355

Outcome results